In addition, EntreMed scientists are scheduled for the following poster
-- "ENMD-1198 Antitumor Activity and Inhibition of HIF-1alpha, STAT3 and
NFkappaB Signaling Pathways are Dependent on Microtubule Isotype
Expression and Targeting," Monday, April 14, 2008 from 1:00 PM -
-- "Combination Therapy of MKC-1 and Paclitaxel Synergistically Inhibits
Tumor Growth in the MDA-MB-231 Orthotopic Breast Cancer Tumor Model,"
Tuesday, April 15, 2008, 8:00 AM - 12:00 PM.
Dr. Bray's presentation, as well as the poster presentations, will be available on the Company's web site at http://www.entremed.com.
EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.
Forward Looking Statements
This release contains forward-looking statements within the meaning of
the Private Securities Litigatio
|SOURCE EntreMed, Inc.|
Copyright©2008 PR Newswire.
All rights reserved